StockrabitBrowse analysts
Analyst questions

Vinod Jain

Wells Fargo Advisors
PPLPHARMA

Piramal Pharma Limited

All company calls
Piramal Pharma Limited CC-Sep23.pdf
30 Oct 2023
Open call
  1. I wish to ask on the financial side the question. You have had a situation where H1 and H2 phenomena continues over the years where H1 delivers much lower returns than H2. Now going forward, how do we look at it? Is this going to change, or it will continue because it affects the annual working of the company?

    Read in transcript
  2. So, is there any possibility of further cost reduction in the first half? Because the first half typically shows negative results and that hurts all working out, of course.

    Read in transcript